Progressive Supranuclear Palsy

Progressive Supranuclear Palsy (PSP) is a rare neurodegenerative disorder that affects movement, gait, balance, and speech. Discover the latest research on PSP here.

February 26, 2021
Open Access

In vivo coupling of dendritic complexity with presynaptic density in primary tauopathies.

Neurobiology of Aging
Elijah MakJ. Rowe
February 21, 2021

Lessons learned from a progressive supranuclear palsy trial.

Lancet Neurology
Murray Grossman
February 21, 2021
Open Access

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial.

Lancet Neurology
Günter HöglingerArise Investigators
February 18, 2021

Gender differences in progressive supranuclear palsy.

Acta neurologica Belgica
Rohan R MahaleAsha Kishore
February 17, 2021

Molecular Imaging of Neurodegenerative Parkinsonism.

PET Clinics
Kirk A Frey, Nicolaas I L J Bohnen
February 16, 2021
Open Access

Spatial attention and spatial short term memory in PSP and Parkinson's disease.

Cortex; a Journal Devoted to the Study of the Nervous System and Behavior
Daniel T SmithNeil Archibald
February 14, 2021

Association of PSP phenotypes with survival: A brain-bank study.

Parkinsonism & Related Disorders
Mar GuaspYaroslau Compta
February 13, 2021

Perry syndrome with progressive supranuclear palsy-like phenotype in a Portuguese family - Long-term clinical follow-up.

Parkinsonism & Related Disorders
Rui Duarte BarretoMarina Magalhães
February 12, 2021
Open Access

RT001 in Progressive Supranuclear Palsy—Clinical and In-Vitro Observations.

Plamena AngelovaMisha S. Shchepinov
February 12, 2021

A Systematic Review of Apathy and Depression in Progressive Supranuclear Palsy.

Journal of Geriatric Psychiatry and Neurology
Joshua Flavell, Peter J Nestor
February 12, 2021

Deep Learning-Based Image Classification in Differentiating Tufted Astrocytes, Astrocytic Plaques, and Neuritic Plaques.

Journal of Neuropathology and Experimental Neurology
Shunsuke KogaDennis W Dickson
February 11, 2021
Open Access

Predicting loss of independence and mortality in frontotemporal lobar degeneration syndromes.

Journal of Neurology, Neurosurgery, and Psychiatry
Alexander G MurleyJames B Rowe
February 10, 2021
Open Access

Feasibility of Short Imaging Protocols for [18F]PI-2620 Tau-PET in Progressive Supranuclear Palsy

Mengmeng SongMatthias Brendel
February 10, 2021
Open Access

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias.

Alzheimer's Research & Therapy
Claudia CicognolaKaj Blennow
February 9, 2021

Conventional Magnetic Resonance Imaging in the Diagnosis of Parkinsonian Disorders: A Meta-Analysis.

Movement Disorders Clinical Practice
Will Lee

Sign up to follow this feed and discover related papers.

Related Feeds

22q11 Deletion Syndrome

22q11.2 deletion syndrome, also known as DiGeorge syndrome, is a congenital disorder caused as a result of a partial deletion of chromosome 22. Here is the latest research.

3D Cellular Models of Brain and Neurodegeneration

Brain organoids are three-dimensional in vitro cellular models of the brain that can recapitulate many processes such as the neurodevelopment. In addition, these organoids can be combined with other cell types, such as neurons and astrocytes to study their interactions in assembloids. Disease processes can also be modeled by induced pluripotent stem cell-derived organoids and assembloids from patients with neurodegenerative disorders. Discover the latest research on the models here.

4H Leukodystrophy

4H Lekodystrophy involves hypomyelination, hypogonadotropic hypogonadism and hypodontia. It is also known as POLR-3Related Leukodystrophy. 4H syndrome symptoms include delayed or abnormal puberty, issues with central nervous system signal transmission, abnormal development of teeth, and symptoms tend to progressively get worse over time. There is not yet a known cure.


TAR DNA-binding protein 43 (TDP-43) is a pathological protein identified in sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Here are the latest discoveries pertaining to TDP-43 and these diseases.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Pathogenic Mechanisms

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS: Phenotypes

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized phenotypically by progressive muscle weakness. Clinical phenotypes of ALS can be classified based on the pattern, level, and area of onset (e.g. bulbar, cervical, lumbar). Here is the latest research investigating phenotypes of ALS.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here is the latest research on ALS and prions.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research in this field.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

© 2021 Meta ULC. All rights reserved